The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
August 18, 2025
Linvoseltamab (Lynozyfic) for Multiple Myeloma (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Linvoseltamab (Lynozyfic) for Multiple Myeloma (online only)
August 18, 2025 (Issue: 1735)
Linvoseltamab (Lynozyfic – Regeneron), a bispecific
B-cell maturation antigen (BCMA)-directed CD3
T-cell engager, has received accelerated approval
from the FDA for intravenous treatment of relapsed
or refractory multiple myeloma in adults...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.